bioRxivImmunology
Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.
B. Trinite, E. Pradenas, S. Marfil, C. Rovirosa, V. Urrea, F. Tarres-Freixas, R. Ortiz, J. Vergara-Alert, J. Segales, V. Guallar, A. Lepore, N. Izquierdo-Useros, G. Trujillo, J. Trape, C. Gonzalez-Fernandez, A. Flor, R. Perez-Vidal, A. Chamorro, R. Toledo, R. Paredes, I. Blanco, E. Grau, M. Massanella, J. Carrillo, B. Clotet, J. Blanco
Abstract
To assess the potential impact of predominant circulating SARS-CoV-2 variants on neutralizing activity of infected and/or vaccinated individuals, we analyzed neutralization of pseudoviruses expressing the spike of the original Wuhan strain, the D614G and B.1.1.7 variants. Our data show that parameters of natural infection (time from infection and infecting variant) determined cross-neutralization. Importantly, upon vaccination, previously infected individuals developed equivalent B.1.1.7 and Wuhan neutralizing responses. In contrast, uninfected vaccinees showed reduced neutralization against B.1.1.7. FundingThis study was funded by Grifols, the Departament de Salut of the Generalitat de Catalunya, the Spanish Health Institute Carlos III, CERCA Programme/Generalitat de Catalunya, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat and Correos.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
D. Planas, T. Bruel, … O. Schwartz·bioRxiv·Feb 12, 2021
- SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Strain-specific Neutralizing Antibodies in Naïve and Previously Infected Recipients
T. M. Narowski, K. Raphel, … L. Premkumar·bioRxiv·Jun 19, 2021
- Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant
V. V. Edara, C. Norwood, … M. S. Suthar·bioRxiv·Feb 20, 2021
- Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine
G. Sapkal, P. Yadav, … B. Bhargava·bioRxiv·Apr 30, 2021
- Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2
F. Amanat, S. Strohmeier, … F. Krammer·bioRxiv·Aug 5, 2021
- Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant
V.-V. Edara, L. Lai, … M. Suthar·bioRxiv·May 9, 2021